OncRef
Skip to newsletter content
|
NSCLCFebruary 2026
0:00 / 4:16
Non-Small Cell Lung Cancer — Monthly Compass
Feb 01–28, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in non-small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
non-small cell lung cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • On February 26, 2026, the FDA granted accelerated approval to zongertinib (Hernexeos) as the first targeted initial treatment for adults with unresectable or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD-activating mutations, supported by a 76% ORR in treatment‑naïve patients from Beamion LUNG‑1 and expedited via Real‑Time Oncology Review, Priority Review, and the Commissioner’s National Priority Voucher with a 44‑day review.
    • On February 17, 2026, the FDA approved once‑monthly subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase‑lpuj), establishing the only EGFR‑targeted therapy deliverable monthly from week 5 while maintaining efficacy and markedly reducing administration‑related reactions versus historical IV dosing.
  • Important Drug Publication Updates
    • A MARIPOSA Phase 3 subset analysis showed amivantamab plus lazertinib achieved a statistically significant, clinically meaningful overall survival advantage over osimertinib in previously untreated Asian patients with EGFR‑mutated advanced NSCLC, representing the first regimen to surpass osimertinib in this population.
  • Key Clinical Development Updates
    • The FDA accepted Summit Therapeutics’ BLA for ivonescimab (SMT112) plus chemotherapy in EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC after prior EGFR TKI therapy, assigning a PDUFA goal date of November 14, 2026 based on the Phase 3 HARMONi trial.
    • The FDA cleared CStone’s IND for CS2009, a PD‑1/VEGF/CTLA‑4 trispecific antibody, enabling a global Phase II program across nine solid tumor indications including NSCLC with multiple monotherapy and combination cohorts.
  • Important Clinical Trial Publications
    • The Phase 3 ARTS trial demonstrated that adjuvant aumolertinib significantly prolonged disease‑free survival versus placebo in resected stage II–IIIB EGFR‑mutated NSCLC (HR 0.17; 95% CI 0.09–0.29) with a manageable safety profile.
    • A randomized Phase 3 trial found morning (pre‑15:00) administration of immunochemotherapy significantly improved progression‑free and overall survival in advanced NSCLC compared with late‑day dosing, aligning with circadian‑linked CD8+ T‑cell activity.
  • Key Conference Updates
    • TTLC 2026 debates highlighted a frontline inflection point for HER2 exon 20 and EGFR exon 20 insertion NSCLC, balancing high‑response, intracranially active next‑generation TKIs against amivantamab‑chemotherapy anchors and favoring ADC/TKI combinations to address heterogeneity and resistance.
    • Sessions emphasized KRAS program diversification beyond G12C, with real‑world analyses indicating earlier time‑to‑next‑treatment and overall survival advantage for G12D and distinct STK11/KEAP1 co‑mutation patterns informing stratified study designs.
  • Emerging Themes & Macro-Trends
    • Health‑system priorities are shifting toward expanded NGS and liquid biopsy capacity for rare‑driver capture and resistance tracking alongside readiness for ADC‑TKI and TKI‑chemotherapy combination trials.
    • Operational simplification via subcutaneous, less‑frequent dosing is accelerating precision NSCLC adoption and may prompt pathway and guideline updates.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • The FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.) for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations. This approval was based on efficacy data from the Beamion LUNG-1 trial, which showed an objective response rate of 76% in the study population.¹ (read more)
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • FDA granted accelerated approval to Boehringer Ingelheim’s zongertinib (Hernexeos) for adults with unresectable or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD-activating mutations; the filing used Real-Time Oncology Review and received Priority Review, and efficacy in Beamion LUNG-1 showed a 76% ORR in treatment‑naïve patients.¹ (read more)
  • FDA issued a news release highlighting that Hernexeos (zongertinib) was approved under the Commissioner’s National Priority Voucher pilot program for NSCLC, noting the application was filed on January 13, 2026, and a final decision was rendered 44 days later; the agency reiterated accelerated approval and Priority Review for this indication.² (read more)
  • Boehringer Ingelheim announced FDA approval of HERNEXEOS as the first targeted initial treatment option for HER2‑mutant advanced NSCLC and noted both Breakthrough Therapy Designation and receipt of a Commissioner’s National Priority Voucher supporting expedited review.³ (read more)
  • Summit Therapeutics reported that FDA accepted its BLA for ivonescimab (SMT112) plus chemotherapy in EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC after prior EGFR TKI therapy; FDA assigned a PDUFA goal date of November 14, 2026, with the submission based on the Phase 3 HARMONi trial.⁴ (read more)
  • CStone Pharmaceuticals announced FDA IND clearance for CS2009, a PD‑1/VEGF/CTLA‑4 trispecific antibody, enabling a global Phase II trial across 9 solid tumor indications including NSCLC; the program advances multiple monotherapy and combination cohorts.⁵ (read more)
Conference
Major Conference Updates
Conference Information
  • IASLC 2026 Targeted Therapies of Lung Cancer (TTLC 2026), Huntington Beach, California; February 18–21, 2026. (read more)
  • Overall, TTLC 2026 emphasized acceleration of precision NSCLC care—bispecifics/ADCs maturing into earlier lines and operational advances (subcutaneous, monthly dosing) improving real‑world access and adherence. (read more)
  • Theme 1: EGFR Bispecifics + Subcutaneous Delivery Simplify First‑Line Care
    • Significance: Once‑monthly RYBREVANT FASPRO (amivantamab and hyaluronidase‑lpuj) with LAZCLUZE (lazertinib) reduces visit burden and administration‑related reactions (ARRs), creating a patient- and clinic‑friendly first‑line option for EGFR‑mutated advanced NSCLC. (read more)
    • Mechanism insights / clinical impact: Amivantamab (EGFR/MET bispecific, immune‑engaging) given subcutaneously via rHuPH20 maintains efficacy with monthly dosing from week 5 and shows markedly lower ARRs versus historical IV amivantamab; aligns with MARIPOSA phase 3 survival benefits that established clinical value of amivantamab‑based regimens. (read more)
    • Patient populations affected: First‑line EGFR‑mutated (exon 19 deletion/L858R) advanced NSCLC in the U.S., with global uptake expected as SC amivantamab options expand. (read more)
  • Theme 2: Early‑Stage Targeted Intensification (Adjuvant/Perioperative)
    • Significance: TTLC highlighted renewed focus on perioperative therapy; contemporaneous data spotlight adjuvant third‑generation TKIs as a strategy to curb recurrence after resection in EGFR‑mutated disease. (read more)
    • Mechanism insights / clinical impact: In the ARTS phase III trial, aumolertinib (3rd‑gen EGFR TKI) delivered major disease‑free survival benefit (HR 0.17; 95% CI 0.09–0.29) with manageable safety—signaling competitive pressure on existing adjuvant paradigms and a potential for region‑to‑global translation. (read more)
    • Patient populations affected: Resected stage II–IIIB, EGFR‑mutated NSCLC (initially Chinese centers) with implications for worldwide adjuvant standards pending regulatory pathways. (read more)
  • Theme 3: Rare‑Driver First‑Line Strategies—TKIs vs Antibody/ADC Combinations
    • Significance: TTLC debates underscored an inflection point for HER2 and EGFR exon 20 insertion disease—whether to move novel TKIs frontline or retain amivantamab‑chemotherapy (PAPILLON) as anchor therapy. (read more)
    • Mechanism insights / clinical impact: Next‑gen TKIs (zongertinib, sevabertinib, zipalertinib, sunvozertinib, furmonertinib) show high response rates and intracranial activity with improved tolerability vs legacy agents; combination strategies (including with trastuzumab deruxtecan) are favored to address heterogeneity/resistance. (read more)
    • Patient populations affected: Frontline HER2 exon 20 and EGFR exon 20 insertion NSCLC globally; decisions hinge on CNS control, toxicity, and durability relative to amivantamab‑based regimens. (read more)
  • Theme 4: KRAS Diversification and Biomarker Infrastructure
    • Significance: TTLC discussions and new analyses reinforce momentum beyond KRAS G12C toward allele‑specific development and resistance‑aware trial design. (read more)
    • Mechanism insights / clinical impact: Real‑world modeling suggests KRAS G12D may have early TTNT advantage and improved OS vs G12C, with distinct co‑mutation (STK11/KEAP1) patterns—supporting precision combinations and stratified studies. (read more)
    • Patient populations affected: Advanced KRAS‑mutant NSCLC subsets (G12C and emerging G12D), where NGS/liquid biopsy adoption enables timely allele identification and resistance tracking. (read more)
  • Significance
    • Expected clinical or translational readouts: Frontline EGFR/HER2 exon 20 TKI trials (e.g., zipalertinib+chemo, sunvozertinib, furmonertinib) highlighted at TTLC are poised for 2026 updates; watch perioperative/adjuvant EGFR programs building on ARTS signals. (read more)
    • Regulatory or policy implications: U.S. approval of once‑monthly RYBREVANT FASPRO may prompt pathway/guideline updates and rapid community adoption given operational advantages. (read more)
    • Potential shifts in standard of care: For 1L EGFR‑mutated NSCLC, SC bispecific+TKI regimens could become default; in exon 20 disease, outcomes of ongoing TKI programs will determine if they challenge amivantamab‑chemotherapy. (read more)
    • Strategic implications: Invest in SC delivery workflows; expand NGS/liquid biopsy capacity for rare‑driver capture; position for ADC‑TKI and TKI‑chemo combination trials to manage resistance. (read more)
Publications Related to Approved Drugs
Phase 3
amivantamab, lazertinib
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis In this subset analysis of the Phase 3 MARIPOSA study, the combination of amivantamab and lazertinib demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib in Asian patients with previously untreated EGFR-mutated advanced NSCLC. These findings establish this combination as the first regimen to show a survival benefit over osimertinib in this specific population, supporting its use as a potential new standard of care. ()
PHASE1, PHASE2
repotrectinib
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial The registrational TRIDENT-1 trial reports that repotrectinib achieves durable systemic and intracranial responses with a manageable safety profile in patients with NTRK fusion-positive solid tumors, including those with solvent front mutations and prior TKI treatment. These results support the therapeutic use of repotrectinib for patients with NTRK-positive disease, addressing the challenge of resistance to early-generation TRK inhibitors. ()
Phase 3
osimertinib
Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China Real-world data from the China Multicentre Lung Cancer Precision Medicine Registry indicates that while first-generation EGFR-TKIs combined with chemoradiotherapy improve progression-free survival compared to chemoradiotherapy alone in unresectable Stage III EGFR-mutated NSCLC, survival outcomes remain limited. This study highlights the treatment landscape following the LAURA study and underscores the persistent unmet need for optimized therapeutic sequencing and third-generation EGFR-TKI integration in this setting. ()
New Publications Related to Drugs in Clinical Trial Development
Here are the key publication updates for non-small cell lung cancer (NSCLC) from February 1, 2026, to February 28, 2026:
Phase 1
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review. Zongertinib, a novel oral HER2-selective tyrosine kinase inhibitor, demonstrated durable clinical activity and a manageable safety profile in the Beamion LUNG-1 trial for patients with HER2-mutant advanced NSCLC, addressing the critical need for agents that spare wild-type EGFR to minimize toxicity. This review details the development leading to its recent approvals and outlines its potential transition to first-line settings. ()
Phase 3
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671. In this Phase 3 analysis, neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab significantly improved event-free survival in resectable stage II-IIIB NSCLC without increasing surgical complications or delays compared to chemotherapy alone. The regimen was associated with a higher rate of R0 resections and improved outcomes regardless of disease stage or nodal status. ()
PHASE1, PHASE2
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial. The combination of the KRASG12C inhibitor glecirasib and the SHP2 inhibitor sitneprotafib achieved a promising objective response rate of 71% in treatment-naïve patients with KRASG12C-mutated NSCLC. The study suggests this chemotherapy-free regimen has a manageable safety profile and warrants further evaluation in Phase 3 trials against standard of care. ()
Phase 3
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial. Although the primary survival endpoint was not statistically significant, sacituzumab govitecan demonstrated meaningful benefits in health-related quality of life compared to docetaxel, specifically delaying the deterioration of shortness of breath and fatigue. These patient-reported outcomes support the agent's clinical value in metastatic NSCLC post-platinum and immunotherapy failure. ()
Phase 3
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials. This publication details the pragmatic design of the PROSPECT-LUNG trial, which reduces protocol length by 65% and data collection burden by over 80% compared to traditional Phase 3 trials like ALCHEMIST CHEMO-IO. This streamlined approach aims to enhance trial efficiency and feasibility for perioperative immunotherapy studies in resectable NSCLC. ()
Early Phase 1
Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials. Preclinical data for [177Lu]Lu-AKIR001 demonstrates high, selective tumor uptake and dose-dependent efficacy in CD44v6-expressing xenograft models, including complete regression in radioresistant models. These findings provide the rationale for the currently recruiting Phase 1 trial targeting CD44v6-positive solid tumors. ()
Phase 3
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. A randomized Phase 3 trial indicates that administering immunochemotherapy in the morning (before 15:00) significantly improves progression-free and overall survival in advanced NSCLC compared to late-day administration. Mechanistic data suggest this benefit is linked to circadian variations in CD8+ T cell activity and immune function. ()
Phase 2
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. The ORCHARD study reports a 47% confirmed objective response rate with the combination of osimertinib and savolitinib in patients with EGFR-mutated NSCLC who developed MET amplification after first-line osimertinib progression. This validates MET amplification as a druggable resistance mechanism and supports this targeted combination strategy. ()
Phase 3
Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer. A cost-effectiveness analysis based on the REZOR trial demonstrates that rezivertinib offers superior quality-adjusted life years (QALYs) compared to gefitinib as a first-line treatment for EGFR-mutated NSCLC. The study concludes that rezivertinib is a cost-effective option within the Chinese healthcare context. ()
Phase 3
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial. In the Phase 3 ARTS trial, adjuvant aumolertinib significantly prolonged disease-free survival (HR 0.17) compared to placebo in patients with resected stage II-IIIB EGFR-mutated NSCLC. The safety profile was consistent with third-generation EGFR TKIs, supporting aumolertinib as a potent adjuvant treatment option. ()
Phase 2
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer. Data from the NADIM II trial establishes minimal residual disease (MRD) status as a critical prognostic marker in resectable NSCLC treated with perioperative chemoimmunotherapy. MRD-negativity was associated with excellent survival outcomes even in patients who did not achieve a pathologic complete response, suggesting MRD can refine risk stratification. ()
Phase 1
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. Dirozalkib, a novel ALK inhibitor, demonstrated a 47.4% objective response rate and a favorable safety profile in a Phase 1 dose-escalation study involving patients with advanced ALK-rearranged NSCLC. The study established 500 mg/day as the recommended Phase 2 dose for further development. ()
Phase 3
Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations. A model-based meta-analysis supports the results of the IPSOS trial, confirming that atezolizumab monotherapy provides a significant overall survival benefit compared to single-agent chemotherapy in vulnerable, platinum-ineligible NSCLC patients. The analysis adjusted for historical control data to validate the non-inferiority and superiority claims of the immunotherapy regimen. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in non-small cell lung cancer updated from 2026-02-01 to 2026-02-28:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation--1---1
Not Yet Recruiting541817-35
Recruiting4737546361181
Available-------
Approved for Marketing-------
Active, Not Recruiting181322118-72
Completed11--5-7
Total7155958661296
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Binimetinib, Palbociclib NCT03170206 COMPLETED Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer 2025-12-31
PF-08046032, Sasanlimab NCT06870487 ACTIVE_NOT_RECRUITING An Open-Label Phase 1 Study to Evaluate PF-08046032 as Monotherapy and Part of Combination Therapy in Participants With Advanced Malignancies 2026-02-27
Oxaliplatin, Leucovorin, Fluorouracil, Zimberelimab, AB598 NCT05891171 ACTIVE_NOT_RECRUITING A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies 2026-03
Oleclumab, Gemcitabine, Nab-paclitaxel, Pemetrexed, Durvalumab, Cisplatin, AZD2936, Carboplatin, Danvatirsen, MEDI5752 NCT03819465 ACTIVE_NOT_RECRUITING A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN) 2026-03-26
Docetaxel, Ceritinib NCT03611738 ACTIVE_NOT_RECRUITING Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC 2026-04
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Toripalimab NCT05888402 ACTIVE_NOT_RECRUITING The Efficacy and Safety of Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume (Bulky) Local Advanced Non-small Cell Lung Cancer 2026-03-20
Savolitinib + Placebo, Osimertinib + Savolitinib NCT04606771 ACTIVE_NOT_RECRUITING A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib 2026-03-30
Osimertinib, Tepotinib NCT03940703 ACTIVE_NOT_RECRUITING A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2) 2026-05-01
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Atezolizumab, Tiragolumab NCT06267001 COMPLETED A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy 2025-12-16
: Pembrolizumab/Vibostolimab, : Pembrolizumab, Nab-paclitaxel, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel NCT05226598 COMPLETED A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) 2026-01-09
: Pembrolizumab/Vibostolimab, : Pembrolizumab NCT04738487 COMPLETED A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer 2026-01-27
: Pembrolizumab, Olaparib, Pemetrexed, Cisplatin, Carboplatin NCT03976323 COMPLETED A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) 2026-01-29
: Pembrolizumab, Olaparib, Nab-paclitaxel, Placebo, Carboplatin, Paclitaxel NCT03976362 COMPLETED A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 2026-01-30
Docetaxel, DS-1062a NCT04656652 ACTIVE_NOT_RECRUITING Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01) 2026-01-31
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.